These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38517798)

  • 21. Investigating longitudinal changes to frontal cortico-striatal tracts in Huntington's disease: the IMAGE-HD study.
    Tan B; Shishegar R; Oldham S; Fornito A; Poudel G; Georgiou-Karistianis N
    Brain Imaging Behav; 2022 Dec; 16(6):2457-2466. PubMed ID: 35768755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
    Johnson EB; Byrne LM; Gregory S; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RA; Zetterberg H; Tabrizi SJ; Scahill RI; Wild EJ;
    Neurology; 2018 Feb; 90(8):e717-e723. PubMed ID: 29367444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive alterations in white matter microstructure across the timecourse of Huntington's disease.
    Estevez-Fraga C; Elmalem MS; Papoutsi M; Durr A; Rees EM; Hobbs NZ; Roos RAC; Landwehrmeyer B; Leavitt BR; Langbehn DR; Scahill RI; Rees G; Tabrizi SJ; Gregory S
    Brain Behav; 2023 Apr; 13(4):e2940. PubMed ID: 36917716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.
    Scahill RI; Hobbs NZ; Say MJ; Bechtel N; Henley SM; Hyare H; Langbehn DR; Jones R; Leavitt BR; Roos RA; Durr A; Johnson H; Lehéricy S; Craufurd D; Kennard C; Hicks SL; Stout JC; Reilmann R; Tabrizi SJ;
    Hum Brain Mapp; 2013 Mar; 34(3):519-29. PubMed ID: 22102212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment?
    Rees EM; Farmer R; Cole JH; Haider S; Durr A; Landwehrmeyer B; Scahill RI; Tabrizi SJ; Hobbs NZ
    Mov Disord; 2014 Nov; 29(13):1648-54. PubMed ID: 25123926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.
    Coppen EM; Jacobs M; van den Berg-Huysmans AA; van der Grond J; Roos RAC
    Parkinsonism Relat Disord; 2018 Jan; 46():56-61. PubMed ID: 29128164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.
    Sturrock A; Laule C; Wyper K; Milner RA; Decolongon J; Dar Santos R; Coleman AJ; Carter K; Creighton S; Bechtel N; Bohlen S; Reilmann R; Johnson HJ; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Mov Disord; 2015 Mar; 30(3):393-401. PubMed ID: 25690257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Composite UHDRS Correlates With Progression of Imaging Biomarkers in Huntington's Disease.
    Estevez-Fraga C; Scahill RI; Durr A; Leavitt BR; Roos RAC; Langbehn DR; Rees G; Gregory S; Tabrizi SJ
    Mov Disord; 2021 May; 36(5):1259-1264. PubMed ID: 33471951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased perivascular space volume in white matter and basal ganglia is associated with cognition in Parkinson's Disease.
    Donahue EK; Foreman RP; Duran JJ; Jakowec MW; O'Neill J; Petkus AJ; Holschneider DP; Choupan J; Van Horn JD; Venkadesh S; Bayram E; Litvan I; Schiehser DM; Petzinger GM
    Brain Imaging Behav; 2024 Feb; 18(1):57-65. PubMed ID: 37855955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.
    Hobbs NZ; Henley SM; Ridgway GR; Wild EJ; Barker RA; Scahill RI; Barnes J; Fox NC; Tabrizi SJ
    J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):756-63. PubMed ID: 19955112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Score of Perivascular Space Dilatation and White Matter Hyperintensities in Patients with Normal Cognition, Mild Cognitive Impairment, and Dementia.
    Zdanovskis N; Platkājis A; Kostiks A; Šneidere K; Stepens A; Naglis R; Karelis G
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888606
    [No Abstract]   [Full Text] [Related]  

  • 33. Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease.
    Garcia-Gorro C; Llera A; Martinez-Horta S; Perez-Perez J; Kulisevsky J; Rodriguez-Dechicha N; Vaquer I; Subira S; Calopa M; Muñoz E; Santacruz P; Ruiz-Idiago J; Mareca C; Beckmann CF; de Diego-Balaguer R; Camara E
    Neuroimage Clin; 2019; 23():101900. PubMed ID: 31255947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain Alterations in Aged OVT73 Sheep Model of Huntington's Disease: An MRI Based Approach.
    Taghian T; Gallagher J; Batcho E; Pullan C; Kuchel T; Denney T; Perumal R; Moore S; Muirhead R; Herde P; Johns D; Christou C; Taylor A; Passler T; Pulaparthi S; Hall E; Chandra S; O'Neill CA; Gray-Edwards H
    J Huntingtons Dis; 2022; 11(4):391-406. PubMed ID: 36189602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
    D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gray matter alterations in Huntington's disease: A meta-analysis of VBM neuroimaging studies.
    Wang X; Li Y; Li B; Shang H; Yang J
    J Neurosci Res; 2024 Jul; 102(7):e25366. PubMed ID: 38953592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of selective basal ganglia white matter loss in premanifest Huntington's disease.
    Zeun P; McColgan P; Dhollander T; Gregory S; Johnson EB; Papoutsi M; Nair A; Scahill RI; Rees G; Tabrizi SJ;
    Neuroimage Clin; 2022; 33():102927. PubMed ID: 34999565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sleep quality, perivascular spaces and brain health markers in ageing - A longitudinal study in the Lothian Birth Cohort 1936.
    Aribisala BS; Valdés Hernández MDC; Okely JA; Cox SR; Ballerini L; Dickie DA; Wiseman SJ; Riha RL; Muñoz Maniega S; Radakovic R; Taylor A; Pattie A; Corley J; Redmond P; Bastin ME; Deary I; Wardlaw JM
    Sleep Med; 2023 Jun; 106():123-131. PubMed ID: 37005116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.